LBA4 Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC

H.H.F. Loong, Keiko Goto, Benjamin Solomon, K. Park, M. Pérol, Edurne Arriola, Silvia Novello, Ying Cheng, Andrea Ardizzoni, Milena Perez Mak, Fernando C. Santini, Yasir Y. Elamin, A. Drilon, J. Wolf, Baohui Han, Hui Han, M. Uh, Tarun Puri, V. Ilaria, C. Zhou